Top Suppliers:I want be here

37415-62-6

37415-62-6 structure
37415-62-6 structure
  • Name: MYCOPHENOLATE SODIUM
  • Chemical Name: mycophenolate sodium
  • CAS Number: 37415-62-6
  • Molecular Formula: C17H20NaO6+
  • Molecular Weight: 343.32700
  • Catalog: Signaling Pathways Anti-infection Bacterial
  • Create Date: 2018-07-25 20:41:37
  • Modify Date: 2024-01-04 18:23:16
  • Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].

Name mycophenolate sodium
Synonyms mycophenolicmonosodiumsalt
MYCOPHENOLATE SODIUM
Mycophenolic acid monosodium salt
sodiummycophenolate
mycophenolicacidmonosodiumsalt
Description Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].
Related Catalog
In Vitro Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus[1]. IMPDH is the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides[2]. Mycophenolic acid (0.01-1 μM; 72 hours) sodium exhibits preferential antiproliferative activity against the endothelial cells and fibroblasts. Endothelial cells are most sensitive cells to Mycophenolic acid treatment with an IC50 <500 nM for antimitotic effects[2]. Fibroblasts are also prone to Mycophenolic acid-induced cell cycle inhibition but exhibit a higher IC50 (<1 μM) compared with endothelial cells. The two human tumor cell lines A549 non-small cell lung cancer cells and PC3 prostate cancer cells show intermediate sensitivity with an IC50 >1 μM. U87 glioblastoma cells are resistant against Mycophenolic acid sodium treatment up to 1 μM[2]. Mycophenolic acid (0.05-2 μM; 18 hours) sodium exhibits a dose-dependent down-regulation of HDAC2 and MYC, whereas up-regulates NDRG1[2]. Cell Proliferation Assay[2] Cell Line: Primary isolated human dermal microvascular endothelial cells (HDMVEC) , fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells, A549 non-small cell lung cancer cells. Concentration: 0.01, 0.1, 1 μM Incubation Time: 72 hours Result: Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity. Western Blot Analysis[2] Cell Line: HDMVEC Concentration: 0, 0.05, 0.1, 0.5, 1, and 2 μM Incubation Time: 18 hours Result: Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1.
In Vivo Mycophenolic acid (120 mg/kg; oral gavage; b.i.d.) sodium exerts its antitumor effects via modulation of the tumor microenvironment, U87 tumor growth is markedly inhibited in vivo in BALB/c nude mice[2]. Animal Model: Athymic 8-week-old, 20 g BALB/c nu/nu mice bearing Mycophenolic acid-resistant human U87 tumor model[2] Dosage: 120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) Administration: Oral gavage; b.i.d. Result: MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (∼70% after day 14 after tumor implantation) in MMF-treated versus control mice. Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively).
References

[1]. Stephen R Welch, et al. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses. 2021 Jun 28;13(7):1255.

[2]. Sophie Domhan, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008 Jun;7(6):1656-68.

Density 1.29 g/cm3
Boiling Point 611.6ºC at 760 mmHg
Molecular Formula C17H20NaO6+
Molecular Weight 343.32700
Flash Point 225.8ºC
Exact Mass 343.11600
PSA 93.06000
LogP 2.73320

CHEMICAL IDENTIFICATION

RTECS NUMBER :
MP8100000
CHEMICAL NAME :
4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4 -methyl-, sodium salt
CAS REGISTRY NUMBER :
37415-62-6
LAST UPDATED :
199606
DATA ITEMS CITED :
6
MOLECULAR FORMULA :
C17-H19-O6.Na
MOLECULAR WEIGHT :
342.35
WISWESSER LINE NOTATION :
T56 BVO DHJ FQ G2UY1&2VO HO1 I1 &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1176 mg/kg
TOXIC EFFECTS :
Tumorigenic - active as anti-cancer agent
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
568 mg/kg
TOXIC EFFECTS :
Tumorigenic - active as anti-cancer agent
TYPE OF TEST :
LD - Lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Rodent - mouse Fibroblast
DOSE/DURATION :
100 ug/L
REFERENCE :
BIJOAK Biochemical Journal. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1906- Volume(issue)/page/year: 113,515,1969 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 83943 No. of Facilities: 33 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 99 (estimated)
RIDADR UN 2811 6.1 / PGIII